News
Press Releases
10/25/2024
The RD Fund Announces Ocuphire Pharma’s Acquisition of Opus Genetics
10/16/2023
The Retinal Degeneration Fund Announces an Investment in NVasc
08/24/2023
The Retinal Degeneration Fund announces an investment in Amber Bio
02/28/2023
RD Fund Appoints Mark S. Blumenkranz, MD, MMS to Board of Directors
01/06/2023
The Retinal Degeneration Fund invests in a $78M Series B for Perceive Biotherapeutics
11/10/2022
Foundation Launching its Largest Natural History Study to Date for 1,500 People with Inherited Retinal Diseases Caused by Rare Mutated Genes
09/15/2022
RD Fund Participates in a €75 Million Series B for SparingVision
07/21/2022
RD Fund Announces New Chair, and Expansion of Board of Directors
06/21/2022
Foundation Fighting Blindness Announces Leadership Changes
06/15/2022
Nacuity Pharmaceuticals Announces $16.5 Million Series B Financing Led by Foundation Fighting Blindness & RD Fund
03/08/2022
Foundation Fighting Blindness and InformedDNA Partner to Engage and Screen Patients for ProQR’s Pivotal Usher Syndrome and Retinitis Pigmentosa Clinical Trials
01/19/2022
Foundation Fighting Blindness Promotes Jason Menzo to President and Chief Operating Officer
01/06/2022
RD Fund Announces Series B Financing Behind SalioGen Therapeutics
10/28/2021
RD Fund Announces Fundraising Efforts Underway for RD Fund 2
10/04/2021
RD Fund Appoints Tony Adamis, MD to Board of Directors
09/22/2021
RD Fund Launches Opus Genetics with $19M Seed Funding to Advance Gene Therapy Treatments for Blinding Conditions
10/23/2018
Foundation Fighting Blindness Launches Retinal Degeneration Fund With More Than $70 million of Initial Funding
02/12/2018
Foundation Fighting Blindness will provide up to $7.5 million in funding to develop ProQR’s candidate QR-421a for Usher syndrome type 2A
01/18/2018
Foundation Fighting Blindness Supporting Clinical Development of NACA, Promising New Drug for Many Forms of RP
Load More
Articles
11/13/2024
Nippon Shinyaku and Atsena Therapeutics Enter into an Exclusive Strategic Collaboration for ATSN-101 in the U.S. and Japan
10/24/2024
SparingVision Presents Updates on PRODYGY Trial and PHENOROD2 Study at ESGCT 2024
10/22/2024
Ocuphire Pharma Announces Acquisition of Opus Genetics
09/23/2024
SparingVision Reports Progress on SPVN06 at Major Ophthalmology Conferences
09/05/2024
Atsena Therapeutics Announces 12-Month Safety and Efficacy Data from Phase I/II Clinical Trial of ATSN-101 in LCA1 Published in The Lancet
08/20/2024
Opus Genetics Receives Rare Pediatric Disease Designation from the U.S. FDA for Ocular Gene Therapy OPGx-LCA5 to Treat Rare Inherited Retinal Disease LCA5
08/14/2024
Atsena Therapeutics Receives Rare Pediatric Disease Designation from the U.S. FDA for ATSN-201 Gene Therapy to Treat X-linked Retinoschisis
06/18/2024
Ascidian Therapeutics Enters Collaboration with Roche for Discovery and Development of RNA Exon Editing Therapeutics Targeting Neurological Diseases
06/13/2024
Opus Genetics Announces $1.7 Million in Project-based Funding from the Foundation Fighting Blindness to Support Two Preclinical Programs
05/13/2024
SparingVision Presents One Year Results from the PHENOROD2 Natural History Study and Preliminary SPVN06 Safety Data at Key Congresses
05/01/2024
Atsena Therapeutics Announces Positive Clinical Data from the First Cohort of Phase I/II Trial Evaluating ATSN-201 Gene Therapy for the Treatment of X-linked Retinoschisis (XLRS)
04/30/2024
Nacuity Pharmaceuticals Announces First Patients Implanted in Final Cohort of Phase 1/2 Clinical Trial Evaluating NPI-002 Intravitreal Implant for the Delay of Cataract Progression
04/17/2024
SalioGen Therapeutics Announces Selection Of Development Candidate For ABCA4-Mediated Stargardt Disease
04/16/2024
Nacuity Pharmaceuticals Expands Board of Directors with Appointment of Dr. Emmett Cunningham, Jr.
03/26/2024
Opus Genetics Announces Completion of Dosing in First Cohort of Phase 1/2 Trial of Gene Therapy OPGx-LCA5 in Patients with Rare Inherited Retinal Disease LCA5
02/15/2024
Nacuity Pharmaceuticals Announces Expansion of its Business Advisory Board with Appointment of Rare Disease Advocate Daniel Feller
02/08/2024
SparingVision Presents Initial SPVN06 Safety Data at the Macula Society 47th Annual Meeting
12/08/2023
ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets
12/04/2023
Atsena Therapeutics Announces Positive 12-month Safety and Efficacy Data from Ongoing Phase I/II Clinical Trial of ATSN-101 in Patients with Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D (LCA1)
11/14/2023
Atsena Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ATSN-101 Gene Therapy for GUCY2D-associated Leber Congenital Amaurosis (LCA1)
11/03/2023
New Preliminary Clinical Data on Potential of Opus AAV-based Gene Therapy for Rare Inherited Retinal Disease to be Presented at the American Academy of Ophthalmology Annual Conference 2023
09/26/2023
SparingVision Selects Second Target in Strategic Collaboration with Intellia Therapeutics
09/07/2023
Opus Genetics Announces First Patient Dosed in Phase 1/2 Trial of Gene Therapy OPGx-LCA5 in Patients with Rare Inherited Retinal Disease LCA5
08/30/2023
SparingVision Reports Positive Initial Safety Data from the first cohort treated in its PRODYGY Phase I/II Gene Therapy Trial
08/03/2023
Amber Bio Raises $26 Million Seed Financing Co-Led by Playground Global and Andreessen Horowitz to Advance New RNA-Based Gene Editing Platform
08/01/2023
ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen and Ultevursen Ophthalmic Assets
07/11/2023
Nacuity Pharmaceuticals Advances Phase 1/2 Clinical Trial Evaluating NPI-002 Intravitreal Implant for the Delay of Cataract Progression
06/09/2023
The Retinal Research Community Mourns the Loss of Retinal Research Pioneer Thierry Léveillard
05/31/2023
Nacuity Pharmaceuticals Achieves Target Enrollment for Phase 1/2 Clinical Trial of NPI-001 for the Treatment of Retinitis Pigmentosa Associated with Usher Syndrome
05/22/2023
SparingVision Presents New Data on SPVN20 Program at ASGCT 2023
05/01/2023
Atsena Therapeutics Receives FDA Clearance of IND Application for ATSN-201, an Investigational Gene Therapy for the Treatment of X-linked Retinoschisis
04/27/2023
SparingVision Presents Progress of its Lead Gene Therapy Program SPVN06 at ARVO 2023
04/25/2023
Atsena Therapeutics Announces Positive 6-month Data from Ongoing Phase I/II Clinical Trial of ATSN-101 in Patients with Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D (LCA1)
12/28/2022
Opus Genetics Announces Acquisition of the Rights to Two Gene Therapy Product Candidates for Inherited Retinal Diseases
12/01/2022
SparingVision's lead asset SPVN06 clears IND application in the US for the treatment of retinitis pigmentosa
12/01/2022
Opus Genetics Receives FDA Clearance of IND Application for OPGx-001, a Gene Therapy Candidate Intended for the Treatment of Rare Inherited Retinal Disease LCA5
11/08/2022
Nacuity Pharmaceuticals Expands Board of Directors with Appointment of Dr. Russell Kelley
11/08/2022
Atsena Therapeutics Expands Leadership Team with Appointment of Lis Leiderman, MD, MBA, as Chief Financial Officer and Chief Business Officer
10/12/2022
Ascidian Therapeutics Launches to Rewrite RNA
10/03/2022
Atsena Therapeutics Announces Positive Results from Phase I/II Clinical Trial of ATSN-101 for the Treatment of GUCY2D-associated Leber Congenital Amaurosis (LCA1)
09/27/2022
Opus Genetics Expands Board of Directors with Appointment of Global Ophthalmology Leader Dr. Adrienne Graves
08/12/2022
ProQR to Focus Exclusively on Axiomer RNA-editing Technology and Partner Ophthalmology Programs
07/27/2022
Atsena Therapeutics Announces Opening of New Office and Laboratory Space in North Carolina’s Research Triangle
07/21/2022
Opus Genetics Expands its Leadership Team
07/11/2022
Opus Genetics to Present at OIS Retina Innovation Summit 2022
05/11/2022
Opus Genetics Appoints Jennifer Hunt Chief Development Officer
02/15/2022
Opus Genetics Appoints Brian Leising Vice President, Manufacturing
02/11/2022
ProQR Announces Top-Line Results from Phase 2/3 Illuminate Trial of Sepofarsen in CEP290-mediated LCA10
01/05/2022
SalioGen Therapeutics Closes $115 Million Oversubscribed Series B Financing to Advance Gene Coding™ – A New Category of Genetic Medicine
12/16/2021
ProQR Announces First Patients Dosed in Phase 2/3 Pivotal Trials of QR-421a for USH2A Mediated Retinitis Pigmentosa
12/09/2021
SparingVision Strengthens Leadership Team with the Appointment of Dr Mehdi Gasmi as Chief Operating Officer
12/06/2021
Gyroscope Therapeutics Announces Appointment of Tony Adamis to Board of Directors
12/02/2021
Startup spotlight: Opus Genetics, with $19M, works to advance cures for blinding retinal diseases
11/30/2021
Opus Genetics announces licensing of third program for inherited retinal disease
11/11/2021
Opus Genetics Announces Agreement with Massachusetts Eye and Ear and Harvard Medical School to License Third Program for Inherited Retinal Disease
11/08/2021
Opus Genetics Announces Presence at Eyecelerator@AAO 2021
10/28/2021
Pfizer, Novartis sign on to accelerate gene therapies for rare diseases with US agencies
10/20/2021
Opus Genetics Announces Two Key Leadership Appointments
10/13/2021
Intellia beefs up ocular pipeline with 10% stake in SparingVision
10/13/2021
Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology
10/04/2021
ProQR Appoints Theresa Heggie as Chief Commercial Officer
09/22/2021
Luxturna inventor Jean Bennett starts a new gene therapy company to tackle rare diseases left behind by pharma, VCs
07/29/2021
To Get New Treatments Across the Finish Line, a Funder Fighting Blindness Turns to Investing
07/12/2021
Atsena Therapeutics Appoints Jennifer Wellman to Board of Directors
06/04/2021
Venture philanthropy: The secret weapon for unlocking biomedical research's full life-changing potential
05/18/2021
Vedere Bio II Launches with $77 Million Series A Financing to Develop Next Generation Ocular Gene Therapies
03/24/2021
ProQR Announces Positive Results from Clinical Trial of QR-421a in Usher Syndrome and Plans to Start Pivotal Trials
03/19/2021
SparingVision Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting
02/04/2021
Dr Daniel C. Chung appointed as Chief Medical Officer of SparingVision
01/29/2021
Renowned Pioneers in Ophthalmology Join SparingVision’s Scientific Advisory Board
12/16/2020
Atsena Therapeutics Raises $55 Million Series A Financing to Advance LCA1 Gene Therapy Clinical Program, Two Preclinical Assets, and Novel Capsid Development for Ocular Diseases
11/09/2020
Stargazer Pharmaceuticals, Inc. Announces $57 Million Series A Financing and Initiation of a Phase 2a Clinical Study of STG-001 in Stargardt Disease Patients
10/29/2020
Novartis Acquires Vedere Bio, a Novel Optogenetics AAV Gene Therapy Company
10/21/2020
SparingVision Raises €44.5 Million and Appoints Stéphane Boissel as Chief Executive Officer
07/29/2020
Atsena Therapeutics acquires exclusive rights to Gene Therapy for GUCY2D-associated Leber Congenital Amaurosis
05/18/2020
Nacuity Pharmaceuticals Announces Initiation of SLO-RP (Safety and Efficacy of NPI-001 Tablets versus PLacebO for Treatment of Retinitis Pigmentosa Associated with Usher Syndrome) Phase 1/2 Clinical Trial
04/28/2020
CheckedUp Launches Virtual Visits, Advanced Telehealth Platform for Specialty Care
03/31/2020
ProQR Announces Positive Findings From an Interim Analysis in the Phase 1/2 trial of QR-421a for Usher Syndrome and Provides Business Update
07/09/2019
SparingVision Awarded at EIC Accelerator Program (H2020 SME Instrument Phase 2), Securing Funding of €2.5 Million
03/11/2019
ProQR Doses First Patient in Phase 1/2 STELLAR Trial of QR-421a for Usher Syndrome Type 2
07/12/2017
SparingVision Formed to Advance Sight-Saving Protein for RP
Load More